Your session is about to expire
← Back to Search
Tremelimumab for Mesothelioma (Tremelimumab Trial)
Tremelimumab Trial Summary
This trial is testing a new cancer drug for people with mesothelioma who can't have surgery. 564 people will be enrolled and randomly assigned to either receive the drug or a placebo. There will be follow-ups to check safety and long-term effects.
Tremelimumab Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTremelimumab Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 33 Patients • NCT03007407Tremelimumab Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a bad reaction to drugs similar to tremelimumab in the past.I don't have lasting side effects from cancer treatment, except for hair loss or skin color changes.My advanced disease worsened after 1-2 treatments including a pemetrexed-platinum combo.I have or had diverticulitis.I have received treatments targeting immune checkpoints.I have had symptoms of an autoimmune disease in the last 3 years.You have a measurable disease in the chest or abdominal lining.I received my last chemotherapy or radiation less than 2 weeks ago.My cancer, found in the lining of my chest or abdomen, has been confirmed by lab tests.I am 18 years old or older.I have tried more than 2 treatments for advanced mesothelioma without success.I have or had lupus or granulomatosis with polyangiitis.I have a history of sarcoidosis.I am currently on steroids or other drugs that weaken my immune system.I have not received any live vaccines in the last month.My blood, liver, and kidney tests are all within normal ranges.I don't have any serious illnesses or infections that would stop me from taking a new treatment.I have been cancer-free from another type of cancer for over 3 years.I have or had serious gut conditions like IBD or celiac disease.I am using effective birth control and will continue for 6 months after my last treatment dose.I am a man who can father children and will use effective birth control during and 90 days after treatment.You must have negative test results for HIV, hepatitis A, B, and C.I have recovered from previous cancer treatment side effects, except for minor ones.My condition cannot be cured with surgery.I am fully active or can carry out light work.I have brain metastases that haven't been treated.
- Group 1: Tremelimumab
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the age limit for this research extend beyond 65 years old?
"The specific age range for this clinical trial is much larger than average, as it encompasses patients from 18 to 99 years old. There are 49 other trials underway for people who are under 18 and 1742 different ones for patients over 65."
Are there any positions available for participants in this research?
"Currently, this study is not looking for new patients according to the clinicaltrials.gov website. The trial was first posted on May 17th, 2013 and last edited on August 30th, 2022. Even though this specific study isn't taking candidates, there are 1,749 other trials that are actively recruiting right now."
Is Tremelimumab a new or experimental medication?
"Tremelimumab was first investigated in 2007 at Research Site. Since then, there have been 18353 completed studies on the medication. As of now, 94 clinical trials are ongoing; a majority of these are located in Sainte Foy, Quebec."
Is this a ground-breaking clinical trial?
"Tremelimumab has been under medical research scrutiny since 2007. A trial was completed in that year, with AstraZeneca footing the bill. 37 people were involved in the first study. After Phase 2 drug approval, 94 active studies involving 263 cities and 48 countries began to use Tremelimumab."
In how many different medical clinics is this clinical study being conducted today?
"Currently, this clinical trial is enrolling patients at 22 sites which are situated in cities including Sainte Foy, Philadelphia and La Jolla. If you choose to enroll in the trial, it may be advantageous to select a location nearest to you so as to reduce travel time commitment."
What is the limit to how many patients can join this experiment?
"Unfortunately, this study is no longer admitting patients. The listing was created on May 17th, 2013 and last updated on August 20th, 2022. For those still seeking studies, there are 1655 active clinical trials for lung cancer and 94 actively enrolling Tremelimumab candidates."
What have been the most common side effects that patients experience with Tremelimumab?
"Tremelimumab's safety is rated as a 2 by our team at Power. While there isn't data attesting to its efficacy, tremelimumab has undergone some clinical trials that support its safety."
How can I get involved with this clinical trial?
"The ideal candidate for this particular clinical trial would be between the ages of 18 and 99, has a diagnosis of lung cancer, and there are 571 total patients being sought."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger